These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 4074615)

  • 1. The influence of age and smoking on the elimination of disopyramide.
    Bonde J; Pedersen LE; Bødtker S; Angelo HR; Svendsen TL; Kampmann JP
    Br J Clin Pharmacol; 1985 Nov; 20(5):453-8. PubMed ID: 4074615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of disopyramide in decreased hepatic function.
    Bonde J; Graudal NA; Pedersen LE; Balsløv S; Angelo HR; Svendsen TL; Kampmann JP
    Eur J Clin Pharmacol; 1986; 31(1):73-7. PubMed ID: 3780831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.
    Lima JJ; Haughey DB; Leier CV
    J Pharmacokinet Biopharm; 1984 Jun; 12(3):289-313. PubMed ID: 6502472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disopyramide pharmacokinetics and metabolism: effect of inducers.
    Kapil RP; Axelson JE; Mansfield IL; Edwards DJ; McErlane B; Mason MA; Lalka D; Kerr CR
    Br J Clin Pharmacol; 1987 Dec; 24(6):781-91. PubMed ID: 3440098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atenolol inhibits the elimination of disopyramide.
    Bonde J; Bødtker S; Angelo HR; Svendsen TL; Kampmann JP
    Eur J Clin Pharmacol; 1985; 28(1):41-3. PubMed ID: 3987784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment?
    Braun J; Sörgel F; Gluth WP; Oie S
    Eur J Clin Pharmacol; 1988; 35(3):313-7. PubMed ID: 3181285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disopyramide protein binding in plasma from patients with nephrotic syndrome during the exacerbation and remission phases.
    Echizen H; Saima S; Ishizaki T
    Br J Clin Pharmacol; 1987 Aug; 24(2):199-206. PubMed ID: 3620294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
    Le Corre P; Gibassier D; Sado P; Le Verge R
    Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentration-dependence of disopyramide binding to plasma protein and its influence on kinetics and dynamics.
    Lima JJ; Boudoulas H; Blanford M
    J Pharmacol Exp Ther; 1981 Dec; 219(3):741-7. PubMed ID: 7299695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of disopyramide after intravenous infusion to patients with myocardial infarction and heart failure.
    Bonde J; Angelo HR; Bødtker S; Svendsen TL; Kampmann JP
    Acta Pharmacol Toxicol (Copenh); 1985 Apr; 56(4):278-82. PubMed ID: 4024955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function.
    Pedersen LE; Bonde J; Graudal NA; Backer NV; Hansen JE; Kampmann JP
    Br J Clin Pharmacol; 1987 Jan; 23(1):41-6. PubMed ID: 3814461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients.
    Haughey DB; Kraft CJ; Matzke GR; Keane WF; Halstenson CE
    Am J Nephrol; 1985; 5(1):35-9. PubMed ID: 3881959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction.
    David BM; Ilett KF; Whitford EG; Stenhouse NS
    Br J Clin Pharmacol; 1983 Apr; 15(4):435-41. PubMed ID: 6849779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of disopyramide.
    Siddoway LA; Woosley RL
    Clin Pharmacokinet; 1986; 11(3):214-22. PubMed ID: 3524956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereoselective pharmacokinetics of disopyramide enantiomers in man.
    Lima JJ; Boudoulas H; Shields BJ
    Drug Metab Dispos; 1985; 13(5):572-7. PubMed ID: 2865105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-1-acid glycoprotein concentration and the protein binding of disopyramide in healthy subjects.
    Kishino S; Nomura A; Di ZS; Sugawara M; Iseki K; Kakinoki S; Kitabatake A; Miyazaki K
    J Clin Pharmacol; 1995 May; 35(5):510-4. PubMed ID: 7657852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disopyramide pharmacokinetics in the elderly after single oral administration.
    Roberto P; Vitaliano B; Donatella P; Raffaella M; Sergio B; Gabriella C
    Pharmacol Res Commun; 1988 Dec; 20(12):1025-34. PubMed ID: 3211990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma protein binding of disopyramide in pregnant and postpartum women, and in neonates and their mothers.
    Echizen H; Nakura M; Saotome T; Minoura S; Ishizaki T
    Br J Clin Pharmacol; 1990 Apr; 29(4):423-30. PubMed ID: 2183867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The stereoselective disposition of disopyramide in the dog.
    Giacomini KM; Giacomini JC; Swezey SE; Harrison DC; Nelson WL; Burke TR; Blaschke TF
    J Cardiovasc Pharmacol; 1980; 2(6):825-32. PubMed ID: 6160331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of age and plasma concentrations of albumin and alpha 1-acid glycoprotein on protein binding of disopyramide.
    Holt DW; Hayler AM; Healey GF
    Br J Clin Pharmacol; 1983 Sep; 16(3):344-5. PubMed ID: 6626430
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.